why choose us

300×250 Ad Slot

Drug FDA Status

Showing 60 of 144 result(s) (Page 6 of 15)
Drug Name: Revuforj

Active Ingredient: revumenib

Approval Date: 2024-11-15

Description: To treat relapsed or refractory acute leukemia

Drug Name: Orlynvah

Active Ingredient: sulopenem etzadroxil, probenecid

Approval Date: 2024-10-25

Description: To treat uncomplicated urinary tract infections (uUTI)
Drug Trial Snapshot

Drug Name: Vyloy

Active Ingredient: zolbetuximab-clzb

Approval Date: 2024-10-18

Description: To treat gastric or gastroesophageal junction adenocarcinoma
Drug Trials Snapshots: VYLOY

Drug Name: Hympavzi

Active Ingredient: marstacimab-hncq

Approval Date: 2024-10-11

Description: To prevent or reduce bleeding episodes related to hemophilia A or B
Press Release
Drug Trials Snapshot

Drug Name: Itovebi

Active Ingredient: inavolisib

Approval Date: 2024-10-10

Description: To treat locally advanced or metastatic breast cancer
Drug Trials Snapshot

Drug Name: Flyrcado

Active Ingredient: flurpiridaz F 18

Approval Date: 2024-09-27

Description: A radioactive diagnostic drug to evaluate for myocardial ischemia and infarction

Drug Name: Cobenfy

Active Ingredient: xanomeline and trospium chloride

Approval Date: 2024-09-26

Description: To treat schizophrenia
Press Release
Drug Trials Snapshot

Drug Name: Aqneursa

Active Ingredient: levacetylleucine

Approval Date: 2024-09-24

Description: To treat Niemann-Pick disease type C
Press Release
Drug Trials Snapshot

Drug Name: Miplyffa

Active Ingredient: arimoclomol

Approval Date: 2024-09-20

Description: To treat Niemann-Pick disease type C
Press Release
Drug Trials Snapshot

Drug Name: Ebglyss

Active Ingredient: lebrikizumab-lbkz

Approval Date: 2024-09-13

Description: To treat moderate-to-severe atopic dermatitis
Drug Trials Snapshot

300×250 Ad Slot